Two Sigma Advisers
TMBR

Two Sigma Advisers’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Two Sigma Advisers’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-908
Closed -$17K – 2982
2021
Q4 		$17K Buy
+908
New +$25.7K ﹤0.01% 2553

Other funds holding TMBR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Two Sigma Advisers's TMBR Position: Q1 2022 in Review

Two Sigma Advisers sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q1 2022, closing a stake of 908 shares — an estimated $17K sold.

Two Sigma Advisers first reported a position in TMBR in Q4 2021 and held it in 1 quarter. The position peaked at $17K in Q4 2021. 15 funds tracked by Wall St. Rank hold TMBR as of Q1 2022.

  • Two Sigma Advisers reported no remaining Timber Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 908 Timber Pharmaceuticals, Inc. shares in Q1 2022, an estimated $17K.
  • Two Sigma Advisers first reported a position in Timber Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Two Sigma Advisers's Timber Pharmaceuticals, Inc. position peaked at $17K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.